Article Details

Amphivena's Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at ...

Retrieved on: 2019-06-30 21:07:30

Tags for this article:

Click the tags to see associated articles and topics

Amphivena's Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at .... View article details on hiswai:

Excerpt

<div>... B and C venture financings led by MPM Capital, NanoDimension, <b>Qiming</b> <b>Venture Partners</b> and funds managed by Tekla Capital Management LLC.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo